SB202190 (FHPI): A Benchmark Selective p38 MAPK Pathway Inhibitor

Executive Summary: SB202190 (FHPI, CAS 152121-30-7) is a potent, cell-permeable inhibitor of p38α (IC₅₀ = 50 nM) and p38β (IC₅₀ = 100 nM) mitogen-activated protein kinases (MAPKs) via ATP-competitive binding (Kd = 38 nM) (APExBIO). Its activity modulates signal transduction in inflammation, cell proliferation, apoptosis, and memory pathways (Konstantinidis et al., 2012). SB202190 is insoluble in water but highly soluble in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL). Experimental protocols typically use 5 μM for 72 hours in cell culture or intracerebroventricular injection in animal models. The compound is widely adopted for dissecting p38 MAPK signaling mechanisms, with robust evidence supporting its role in suppressing pro-inflammatory cytokines and modulating apoptosis (See also: SB 202190, PonesimodMolecule).

Biological Rationale

The p38 MAPK pathway is a central regulator of cellular responses to stress, inflammation, and apoptosis. Dysregulation of p38 MAPK signaling is implicated in pathophysiology across cardiovascular disease, cancer, diabetes, sepsis, and neurological disorders (Konstantinidis et al., 2012). Inhibition of p38α and p38β has emerged as a strategy to modulate cell fate by interfering with phosphorylation cascades that control pro-inflammatory cytokine production, cell cycle progression, and programmed cell death. Targeted kinase inhibition enables precise mechanistic interrogation of MAPK-mediated signal transduction in both normal and disease states. SB202190, by virtue of its specificity and permeability, is a cornerstone for such research, as highlighted in advanced assembloid and organoid studies (PD-0325901.com). This article advances prior site content by systematically mapping quantitative inhibitor characteristics to biological outcomes, clarifying where SB202190 outperforms or complements related tools (CyclizineBio).

Mechanism of Action of SB202190 (FHPI)

SB202190 is a pyridinyl imidazole compound that functions as a highly selective ATP-competitive inhibitor of the p38α and p38β isoforms of MAPKs. The compound binds the ATP-binding pocket of these kinases, leading to potent inhibition (IC₅₀ 50 nM for p38α, 100 nM for p38β; Kd = 38 nM for p38 MAPK) (APExBIO). This binding blocks phosphorylation of downstream substrates, thereby halting signal transduction cascades implicated in inflammation, apoptosis, and cellular proliferation. SB202190’s high permeability allows for effective inhibition in cell-based assays and in vivo models. Notably, the compound can also indirectly activate the Raf–MEK–MAPK pathway, resulting in increased phosphorylation of C-Raf and ERK in certain contexts (MAP Kinase Fragment). Its molecular formula is C₂₀H₁₄N₃OF, and its molecular weight is 331.34 g/mol.

Evidence & Benchmarks

• SB202190 inhibits p38α MAPK activity with an IC₅₀ of 50 nM and p38β with an IC₅₀ of 100 nM in biochemical assays (APExBIO, product page).
• p38 MAPK inhibition by SB202190 suppresses the phosphorylation of downstream substrates, modulating inflammatory and apoptotic signaling in vitro (Konstantinidis et al., 2012, Table 1).
• Application of 5 μM SB202190 for 72 hours in cell culture reduces pro-inflammatory cytokine expression and promotes apoptosis in certain cancer cell lines (PonesimodMolecule, Table 2).
• SB202190 exhibits high solubility in DMSO (≥57.7 mg/mL) and ethanol (≥22.47 mg/mL); it is insoluble in water (APExBIO).
• In an animal model, intracerebroventricular injection of SB202190 in rats reduced hippocampal neuronal apoptosis and improved spatial learning and memory, demonstrating neuroprotective potential (Konstantinidis et al., 2012, Fig. 3).
• SB202190 is widely used as a reference compound in apoptosis, inflammation, and cancer research due to its selectivity for p38α/β MAPK isoforms (SP600125.com).

Applications, Limits & Misconceptions

SB202190 is a standard tool for studying the p38 MAPK signaling pathway in inflammation, cancer, apoptosis, and neuroprotection. Its selectivity for p38α and p38β isoforms enables precise dissection of kinase-dependent mechanisms. Researchers leverage SB202190 in:

• MAPK signaling research in cell lines and primary cells.
• Pro-inflammatory cytokine inhibition and inflammation model studies.
• Cancer cell proliferation and apoptosis modulation.
• Neuroprotection and memory research, including vascular dementia models.

This article extends analyses from the CyclizineBio review by providing detailed solubility and storage parameters crucial for reproducibility.

Common Pitfalls or Misconceptions

• SB202190 is ineffective against p38γ and p38δ isoforms at standard concentrations.
• The compound is not soluble in water; DMSO or ethanol are required for stock solutions.
• Long-term storage of SB202190 in solution is not recommended; instability may cause reduced potency.
• Off-target effects may occur at high concentrations (>10 μM); always validate selectivity in context.
• Not suitable for every kinase-driven pathway—its application is restricted to p38α/β MAPK-dependent processes.

Workflow Integration & Parameters

For in vitro assays, SB202190 is typically dissolved in DMSO at 10–50 mM and stored at -20°C for several months; working dilutions (e.g., 5 μM) should be freshly prepared in culture medium. For in vivo studies, dosing regimens (e.g., intracerebroventricular injection) require solubilization in suitable vehicles and careful control of dose (species-dependent). Stock solutions must not be stored long-term at room temperature to avoid degradation. Analytical monitoring (e.g., HPLC) of stock solutions is recommended for reproducibility. The A1632 kit from APExBIO provides quality-controlled SB202190 for research workflows (product page). For advanced applications (e.g., assembloids, organoids), SB202190 enables pathway mapping in complex multicellular systems (PD-0325901.com).

Conclusion & Outlook

SB202190 (FHPI) is a validated, highly selective p38α/β MAP kinase inhibitor. Its robust performance in inflammation, apoptosis, and neuroprotection assays is well documented. The compound's biochemical properties, coupled with precise dosing and solubility protocols, make it a preferred tool for dissecting MAPK signaling. Future work will further define its translational impact in advanced disease models. For detailed protocols and sourcing, refer to SB202190 (FHPI) at APExBIO.